Common use of Inventory Adjustments Clause in Contracts

Inventory Adjustments. Consists of charges or credits due to adjustments to inventory concerning revaluation to new standards, stock conversions, capitalized/amortized production variances, shortages or overages, and damage or obsolescence of regular on-hand inventory or products returned by customers. Each of these charges or credits can be identified to a specific product. Schedule 1.18 PATENT RIGHTS ATHEROGENICS, INC. U.S. PATENT PORTFOLIO AGI 1067 Updated July 1999 DOCKET MATTER NO. TITLE SERIAL FILING PATENT ISSUE RELATED LAST NAME NO. NO. DATE NO. DATE CASES ACTION ---------- ---------- ------------------------ ---------- -------- --------- -------- ---------- -------- ATH100 105001 Treatment for 07/969,934 10/30/92 5,380,747 01/10/95 Patented (EMU110) Atherosclerosis and other Cardiovascular and Inflammatory Diseases --------------------------------------------------------------------------------------------------------------------------------- ATH100 105023 Treatment for 08/722,438 10/17/96 5,877,203 3/2/99 FWC of Patented DIV Atherosclerosis and 08/257,821 other Cardiovascular and Inflammatory Diseases --------------------------------------------------------------------------------------------------------------------------------- ATH101 105012 Treatment for 08/486,239 06/07/95 5,792,787 8/11/98 CON of Patented DIV CON Atherosclerosis and 08/257,821 other Cardiovascular and Inflammatory Diseases --------------------------------------------------------------------------------------------------------------------------------- ATH101 105009 Treatment for 08/477,881 06/07/95 5,783,56 7/21/98 DIV of Patented DIV2 Atherosclerosis and 08/240,858 (ATH101 other Cardiovascular and DIV2) Inflammatory Diseases --------------------------------------------------------------------------------------------------------------------------------- ATH102 105004 Treatment for 08/317,399 10/04/94 5,807,884 9/15/98 CIP of Patented EMU110CIP2 Atherosclerosis and 08/240,858 other Cardiovascular and and CIP of Inflammatory Diseases 07/969,934 --------------------------------------------------------------------------------------------------------------------------------- ATH102 105008 Treatment for 08/483,335 06/07/95 5,811,449 9/22/98 DIV OF Patented DIV1 Atherosclerosis and 08/317,339 other Cardiovascular and Inflammatory Diseases --------------------------------------------------------------------------------------------------------------------------------- ATH102 105028 Treatment for 08/474,530 06/07/95 5,750,351 5/12/98 CON OF Patented CON(1) Atherosclerosis and 08/317,339 other Cardiovascular and Inflammatory Diseases --------------------------------------------------------------------------------------------------------------------------------- ATH102 105006 Treatment for 08/484,059 06/07/95 5,773,209 6/30/98 CON of Patented CON(3) Atherosclerosis and 08/317,339 other Cardiovascular and Inflammatory Diseases --------------------------------------------------------------------------------------------------------------------------------- ATH102 105011 Treatment for 08/473,272 06/07/95 5,773,231 6/30/98 CON of Patented CON(4) Atherosclerosis and 08/317,339 other Cardiovascular and Inflammatory Diseases --------------------------------------------------------------------------------------------------------------------------------- ATH102 105010 Treatment for 08/471,537 06/07/95 5,846,959 12/8/98 CON of Patented CON(5) Atherosclerosis and 08/317,339 other Cardiovascular and Inflammatory Diseases --------------------------------------------------------------------------------------------------------------------------------- ATH103 105016 Soluble Analogs of Probucol 07/876,557 04/30/92 5,262,439 11/16/93 Patented --------------------------------------------------------------------------------------------------------------------------------- [*] [*] [*] [*] [*] [*] --------------------------------------------------------------------------------------------------------------------------------- [*] [*] [*] [*] [*] [*] --------------------------------------------------------------------------------------------------------------------------------- [*] [*] [*] [*] [*] [*] --------------------------------------------------------------------------------------------------------------------------------- ATHEROGENICS, INC. FOREIGN PATENT PORTFOLIO Updated July 1999 DOCKET TITLE COUNTRY SERIAL NO. FILING PUBLICATION LAST NAME & DATE NO. ACTION ------ ------------------- ------- ---------- -------- ----------- --------- [*] ------------------------------------------------------------------------------------------------------ EMU110 Treatment of Hungary P9603041 05/10/95 Published CIP(2) Atherosclerosis and 11/28/97 other Cardiovascular 105005 and Inflammatory Pending Diseases ------------------------------------------------------------------------------------------------------ [*] ------------------------------------------------------------------------------------------------------ 105015 ------------------------------------------------------------------------------------------------------ Schedule 2.1(e) Third Party Agreements License Agreement between Emory University and Atherogenics, Inc., dated January 11, 1995. License to the United States Government dated March 27, 1995. Patent Purchase Agreement between Sampxxx Xxxxxxxxxxxxx, Xx.D. and Atherogenics, Inc., dated April 26, 1995. Schedule 2.6(h) Development Work to be Performed by Licensor Pre-clinical: [ * ] SCHEDULE 2.6(i)

Inventory Adjustments. Consists of charges or credits due to adjustments to inventory concerning revaluation to new standards, stock conversions, capitalized/amortized production variances, shortages or overages, and damage or obsolescence of regular on-hand inventory or products returned by customers. Each of these charges or credits can be identified to a specific product. Schedule 1.18 PATENT RIGHTS ATHEROGENICS, INC. U.S. PATENT PORTFOLIO AGI 1067 Updated July 1999 DOCKET MATTER NO. TITLE SERIAL FILING PATENT ISSUE RELATED LAST NAME NO. NO. DATE NO. DATE CASES ACTION ---------- ---------- ------------------------ ------------------------- ---------- -------- --------- -------- ---------- -------- ATH100 105001 Treatment for 07/969,934 10/30/92 5,380,747 01/10/95 Patented (EMU110) Atherosclerosis and other Cardiovascular and Inflammatory Diseases --------------------------------------------------------------------------------------------------------------------------------- ATH100 105023 Treatment for 08/722,438 10/17/96 5,877,203 3/2/99 FWC of Patented DIV Atherosclerosis and 08/257,821 other Cardiovascular and Inflammatory Diseases --------------------------------------------------------------------------------------------------------------------------------- ATH101 105012 Treatment for 08/486,239 06/07/95 5,792,787 8/11/98 CON of Patented DIV CON Atherosclerosis and 08/257,821 other Cardiovascular and Inflammatory Diseases --------------------------------------------------------------------------------------------------------------------------------- ATH101 105009 Treatment for 08/477,881 06/07/95 5,783,56 7/21/98 DIV of Patented DIV2 Atherosclerosis and 08/240,858 (ATH101 other Cardiovascular and DIV2) Inflammatory Diseases --------------------------------------------------------------------------------------------------------------------------------- ATH102 105004 Treatment for 08/317,399 10/04/94 5,807,884 9/15/98 CIP of Patented EMU110CIP2 Atherosclerosis and 08/240,858 other Cardiovascular and and CIP of Inflammatory Diseases 07/969,934 --------------------------------------------------------------------------------------------------------------------------------- ATH102 105008 Treatment for 08/483,335 06/07/95 5,811,449 9/22/98 DIV OF Patented DIV1 Atherosclerosis and 08/317,339 other Cardiovascular and Inflammatory Diseases --------------------------------------------------------------------------------------------------------------------------------- ATH102 105028 Treatment for 08/474,530 06/07/95 5,750,351 5/12/98 CON OF Patented CON(1) Atherosclerosis and 08/317,339 other Cardiovascular and Inflammatory Diseases --------------------------------------------------------------------------------------------------------------------------------- ATH102 105006 Treatment for 08/484,059 06/07/95 5,773,209 6/30/98 CON of Patented CON(3) Atherosclerosis and 08/317,339 other Cardiovascular and Inflammatory Diseases --------------------------------------------------------------------------------------------------------------------------------- ATH102 105011 Treatment for 08/473,272 06/07/95 5,773,231 6/30/98 CON of Patented CON(4) Atherosclerosis and 08/317,339 other Cardiovascular and Inflammatory Diseases --------------------------------------------------------------------------------------------------------------------------------- ATH102 105010 Treatment for 08/471,537 06/07/95 5,846,959 12/8/98 CON of Patented CON(5) Atherosclerosis and 08/317,339 other Cardiovascular and Inflammatory Diseases --------------------------------------------------------------------------------------------------------------------------------- ATH103 105016 Soluble Analogs of Probucol 07/876,557 04/30/92 5,262,439 11/16/93 Patented Probucol --------------------------------------------------------------------------------------------------------------------------------- [*] [*] [*] [*] [*] [*] --------------------------------------------------------------------------------------------------------------------------------- [*] [*] [*] [*] [*] [*] --------------------------------------------------------------------------------------------------------------------------------- [*] [*] [*] [*] [*] [*] --------------------------------------------------------------------------------------------------------------------------------- ATHEROGENICS, INC. FOREIGN PATENT PORTFOLIO Updated July 1999 DOCKET TITLE COUNTRY SERIAL NO. FILING PUBLICATION LAST NAME & DATE NO. ACTION ------ ------------------- ------- ---------- -------- ----------- --------- [*] ------------------------------------------------------------------------------------------------------ EMU110 Treatment of Hungary P9603041 05/10/95 Published CIP(2) Atherosclerosis and 11/28/97 other Cardiovascular 105005 and Inflammatory Pending Diseases ------------------------------------------------------------------------------------------------------ [*] ------------------------------------------------------------------------------------------------------ 105015 ------------------------------------------------------------------------------------------------------ Schedule 2.1(e) Third Party Agreements License Agreement between Emory University and Atherogenics, Inc., dated January 11, 1995. License to the United States Government dated March 27, 1995. Patent Purchase Agreement between Sampxxx Xxxxxxxxxxxxx, Xx.D. and Atherogenics, Inc., dated April 26, 1995. Schedule 2.6(h) Development Work to be Performed by Licensor Pre-clinical: [ * ] SCHEDULE 2.6(i)